肥胖患者接受再通治疗后的卒中预后
Stroke outcomes in patients with obesity undergoing recanalization therapy
一项前瞻性观察性研究发现,肥胖患者在接受再通治疗后3个月的功能预后较差,1年趋势相似。研究挑战了肥胖悖论,提示肥胖可能与卒中后较差的恢复有关。
Introduction
Obesity is a well-known risk factor for cardiovascular diseases [1]. Despite vigorous public health campaigns advocating healthy lifestyles, obesity rates are rising worldwide, with more than a third of the world’s population now classified as overweight or as individuals with obesity [2]. Using the definition of the World Health Organization (WHO), obesity (body mass index [BMI] ≥30 kg/m²) increased from 9% to 19% in women and from 5% to 14% in men worldwide between 1990 and 2022 [3].
Previously, more favorable outcomes have been reported in patients with obesity compared with normal-weight patients after acute cardiovascular events, including acute ischemic stroke (AIS) [4]. This counterintuitive observation has been described as the “obesity paradox” [5]. This paradox may be related to factors such as greater metabolic reserves and less severe catabolic states during severe illness in patients with obesity. These factors may protect patients with obesity from harmful weight loss and therefore positively influence their prognosis [6]. However, the concept of the obesity paradox in the context of AIS has been challenged in some studies and remains controversial [7, 8]. This is particularly applicable to AIS patients treated with recanalization therapies such as intravenous thrombolysis (IVT) and/or endovascular therapy (EVT) [9,10,11]. Many of the previous studies had methodological limitations, such as reliance on estimated weight or retrospective study designs, highlighting the need for a more robust investigation. Our study therefore aimed to determine the association between obesity and outcome after AIS in patients treated with IVT/EVT.
Methods
Design
The Ischemic Stroke, Obesity and Thrombolysis (ISOT) Study was a prospective, observational clinical study performed at two comprehensive stroke centers in Switzerland (ClinicalTrials.gov registration: NCT04196894). Patients with AIS treated between January 2016 and September 2021 at the participating centers were assessed for eligibility. Patients or their next of kin provided written informed consent prior to enrollment. Patients were included if they had received recanalization therapy (IVT, EVT, or both combined [bridging therapy]) for AIS. Ischemic stroke was defined as the acute onset of neurological deficits due to cerebral ischemia as demonstrated by magnetic resonance imaging (MRI) or computed tomography (CT) [12]. Intravenous thrombolysis was performed with application of alteplase (recombinant tissue plasminogen activator [rt-PA], 0.9 mg/kg; maximum 90 mg) administered as an intravenous bolus (10% of the total dose) followed by a continuous infusion (90% of the total dose) over 1 h [13]. Endovascular techniques comprised mechanical thrombectomy, including the use of stent-retriever devices, aspiration thrombectomy, and combined approaches, and/or the administration of intra-arterial urokinase or rt-PA. The decision to treat was based on the clinical judgment of the treating physicians and the internal guidelines of the participating stroke centers.
Exclusion criteria were as follows: (1) age <18 years (2) evidence of intracranial hemorrhage on baseline imaging, (3) known hemorrhagic diathesis, (4) pre-existing neurological deficits (defined as modified Rankin Scale [mRS] >2 points), (5) uncontrolled arterial hypertension (initial blood pressure >185/110 mmHg or repeatedly elevated pressure despite antihypertensive medication), or (6) severe illness with poor prognosis (e.g., neoplasia). The original target sample size of approximately 750 patients was determined a priori according to the study protocol (NCT04196894). The rationale for calculating the sample size is presented in the supplementary file (Supplementary Methods I).
The study protocol was approved by the local ethics committees in accordance with Swiss regulations (Project ID: PB_2016-01984; Kantonale Ethikkommission Bern). This analysis adhered to the STROBE reporting checklist guidelines for cohort studies.
Measurements
Demographic and baseline clinical characteristics were prospectively collected and included age at admission, sex, stroke severity according to the National Institutes of Health Stroke Scale (NIHSS) score at admission, pre-stroke level of disability (assessed by mRS) and medical history of cardiovascular risk factors (hypertension, diabetes mellitus, hyperlipidemia, history of smoking, known atrial fibrillation, history of chronic heart disease). Time intervals from symptom onset to treatment and from door to treatment were recorded.In case of EVT (including bridging therapy), reperfusion was assessed by the Thrombolysis in Cerebral Infarction (TICI) score, with successful reperfusion defined as TICI scores 2b–3 [14]. Suspected stroke etiology at discharge was classified according to TOAST (Trial of Org 10172 in Acute Stroke Treatment) [15]. Patients were weighed on day 2 of the index AIS hospitalization (day 1 being the day of admission) or as soon as possible thereafter, depending on their ability to stand or sit upright. Patients were weighed again by a study investigator at the 3-month clinical visit. The detailed process of data collection is presented in the Supplementary Methods II.
Outcomes
The primary outcome of this study was poor functional outcome (defined as mRS 3–6) at 3 months. The secondary outcomes were (1) poor functional outcome at 1 year, (2) excellent functional outcome (mRS 0–1) at 3 months and at 1 year, (3) all-cause mortality and (4) occurrence of major adverse cardiovascular events (MACE), defined in this study as a composite of recurrent AIS, occurrence of transient ischemic attack (TIA), symptomatic intracranial hemorrhage (sICH), myocardial infarction and all-cause mortality at 1 year. All deaths were assigned an mRS score of 6. Patients without available mRS data were excluded from the outcome analysis; reasons for missing data included inability to contact the patient or next-of-kin, withdrawal of consent, or incomplete clinical records.
Statistical analysis
The participation rate (consented/approached) and recruitment rate (consented/eligible) were reported.
For the main analysis, we divided the study population into three weight groups according to BMI: normal weight (BMI < 25 kg/m²), overweight (BMI 25.0–29.9 kg/m²), and obesity (BMI ≥ 30 kg/m²). Normal weight served as the reference group for all analyses. Post-hoc power analysis with α = 0.05 was performed by assessing the probability of a noncentral chi-square (X2) distribution for the primary outcome according to the final sample size.
Baseline characteristics for included versus excluded patients and for the three weight groups were reported as median and interquartile range (IQR) for continuous variables, and frequency and percentage for categorical variables. Differences between groups were assessed using Fisher’s exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables.
Logistic regression analysis was used to assess the association between weight group and outcomes. Analysis included multivariable models, with associations reported as adjusted odds ratios (aORs) with their corresponding 95% confidence intervals (CI).
The main multivariable model included age and sex and was named “primary model”. An “extended model” additionally including NIHSS and EVT was performed. The rationale for the extended model is described in the Supplementary Methods III. When the results of the main analysis (three weight group) were not statistically significant, potentially due to the small size of the groups, dichotomous classification of obesity (BMI ≥ 30 vs. <30 kg/m²) was used to confirm the findings.
Because the recommended rt-PA dose for IVT is capped at a maximum of 90 mg (corresponding to a body weight of 100 kg), a subgroup analysis was performed excluding patients weighing ≥100 kg for the main analysis.
No imputation method was used to compensate for missing data. All statistical tests were two-sided, and a p-value < 0.05 was considered statistically significant. All statistical analyses were performed with Stata 17 (StataCorp LLC) and R (version 3.6.0, R Core Team).
Results
Patient characteristics
According to the Study Flowchart (Fig. 1), the participation rate was 2.5% and the recruitment rate was 52%. Of 280 patients initially enrolled in the study, one did not receive recanalization therapy, five were excluded due to missing initial BMI measurements and three were lost to follow-up in the first 3 months. The final study cohort comprised 271 patients, of whom 96 (35%) had normal weight, 113 (42%) were overweight, and 62 (23%) had obesity. Twenty-seven patients were lost to follow-up between the 3-month and 1-year visits and therefore excluded from the 1-year functional outcome analysis.
EVT endovascular treatment, IVT intravenous thrombolysis, ISOT Ischemic Stroke, Obesity and Thrombolysis.
No relevant differences were observed between the included patients (n = 271) and the excluded patients (n = 9, Supplementary eTable I).
Baseline characteristics of the included patients are presented in Table 1. The incidences of all outcome events are summarized in Table 2 for the three weight groups.
Primary outcome
At 3 months, patients with obesity, compared to patients with normal weight, demonstrated higher rates of poor functional outcomes (mRS 3–6) (24% vs 12%; p = 0.03), whereas the rate in overweight patients was comparable to that of normal-weight patients (10%). The distribution of mRS at 3 months across the three weight groups is shown in Fig. 2A. For the three weight groups, the post hoc power analysis based on the observed Χ² was 7.23 at α = 0.05 indicating a statistical power of approximately 67%.
The figure illustrates the distribution of functional outcomes, measured by mRS scores, among patients with normal weight, overweight, and obesity. Distribution of mRS scores at 3 months (A) and at 1 year (B) are shown. Poor functional outcomes (mRS 3–6) were more frequent in patients with obesity at 3 months (24% vs 12% vs 10%, p = 0.03), with a similar non-significant trend at 1 year (24% vs 13% vs 12%, p = 0.11).
In the primary model, obesity, when compared to normal weight, was associated with poor functional outcome at 3 months (aOR 2.82; 95% CI 1.16–6.88; Fig. 3A). Overweight was not associated with poor outcome (aOR 0.99; 95% CI 0.39–2.49). In the extended model additionally adjusted for NIHSS at admission and EVT, the association persisted (obesity vs normal weight: aOR 3.27; 95% CI 1.28–8.35; overweight vs normal weight: aOR 1.23; 95% CI 0.47–3.20, Supplementary eFig. I).
The figure presents forest plots from logistic regression models assessing the relationship between weight group (normal weight as reference) and poor functional outcomes (mRS 3–6), adjusted for age and sex. Data are presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). A Represents the association at 3 months and B at 1 year.
Secondary outcomes
Poor functional outcome at 1 year
The distribution of mRS scores at 1 year across the three weight groups is reported in Fig. 2B.
In the primary model, obesity, when compared to normal weight, showed a trend toward poor functional outcome at 1 year (aOR 2.50; 95% CI 0.98–6.34; Fig. 3B). The association reached significance in the extended model (obesity vs normal weight: aOR 2.69; 95% CI 1.03–7.01, Supplementary eFig. I,I; overweight vs normal weight: aOR 1.12; 95% CI 0.44–2.86). In both models, overweight was not associated with poor outcomes at 1 year (Supplementary Results I). Results from dichotomized obesity analysis (BMI ≥ 30 vs <30 kg/m²) did not differ from the results of the three weight groups for the primary model (Supplementary Results II).
Excellent functional outcome
Patients with obesity achieved less frequently excellent functional outcomes (mRS 0-1) than patients with normal weight at 3 months (76% vs 89%; p = 0.03) but not at 1 year (76% vs 87%; p = 0.11). In the primary model, obesity, when compared to normal weight, was not associated with excellent outcome neither at 3 months (aOR 0.64; 95% CI 0.34–1.23, Supplementary eFig. I,I,I) nor at 1 year (aOR 0.58; 95% CI 0.29–1.18, Supplementary eFig. IV). Extended-model analyses for excellent functional outcome (additionally adjusted for NIHSS and EVT) are reported in Supplementary eFigs. V, VI. In the dichotomized obesity analysis using the primary model, obesity was associated with a lower likelihood of excellent outcome at 3 months (aOR 0.51; 95% CI 0.28–0.93, Supplementary eFig. VII) and at 1 year (aOR 0.46; 95% CI 0.24–0.87, Supplementary eFig. VIII).
Other outcomes
There were no differences among the three weight groups regarding mortality and major cardiovascular events (Supplementary Results III).
Subgroup analysis
Because the recommended rt-PA dose for IVT is capped at a maximum of 90 mg (corresponding to a body weight of 100 kg), a subgroup analysis was performed excluding 22 patients weighing ≥100 kg (remaining N = 249). Obesity, when compared to normal weight, remained associated with poor functional outcome at 3 months in primary model (aOR 3.42; 95% CI 1.33–8.78, Supplementary eFig. IX). At 1 year, a trend toward worse outcome in patients with obesity persisted in the primary model (aOR 2.68; 95% CI 0.97–7.40, Supplementary eFig. X).
Discussion
The aim of this study was to investigate the relationship between obesity and functional outcomes in AIS patients treated with recanalization therapy. The main finding of our study is that in AIS patients undergoing recanalization therapy, obesity was associated with a higher likelihood of poor outcomes (mRS 3–6) at 3 months, with a persistent trend at 1 year. Overweight was not associated with poorer outcomes. No difference was observed in the incidence of MACE and mortality rate between groups during the 1-year follow-up period. The association between obesity and poor outcome at 3 months persisted in a sensitivity analysis restricted to patients weighing <100 kg (aOR 3.42; 95% CI 1.33–8.78), supporting the robustness of our findings even when patients potentially affected by the 90 mg alteplase dose cap were excluded.
The evidence regarding the impact of obesity on functional outcomes after AIS is conflicting [7]. In the TEMPiS trial (Telemedic Pilot Project for Integrative Stroke Care), patients with obesity (BMI 30–35 kg/m²) had a lower risk of death or high dependency defined as needing institutional care and/or an mRS >3 at 30 months (OR 0.60; 95% CI 0.39–0.91) [16]. Similarly, a study by Kim et al. demonstrated that patients with obesity were less likely to have an mRS 3–6 at 3 months (OR 0.54; 95% CI 0.30–0.99) [17]. However, the association was no longer present after adjustment for stroke severity (defined by the NIHSS at enrollment) [17]. The relationship between obesity and outcomes after recanalization therapy has not yet been thoroughly evaluated [18]. Most studies on patients receiving IVT have reported comparable rates of excellent outcomes between individuals with and without obesity [10, 11, 19]. Regarding EVT, its general feasibility and safety in patients with obesity have been well-documented [20]. A post hoc analysis of the MR-Clean Trial observed a trend indicating that higher BMI may be associated with better functional outcomes at 3 months in stroke patients treated with EVT (OR 1.04; 95% CI 1.0–1.09) [11]. Conversely, another study reported a decrease in functional independence (mRS 0–2) with increasing BMI [20].
Seet et al. reported no significant association between BMI categories and functional outcomes in stroke patients treated with IVT after matching for age and NIHSS, but found that poor functional recovery was associated with the number of metabolic syndrome components [21]. Notably, in our three-group analysis, arterial hypertension was significantly more prevalent in patients with obesity compared to those with normal weight (82% vs 64%), suggesting that metabolic comorbidities may contribute to the worse outcomes observed in the obesity group.
Our findings provide exploratory, hypothesis-generating, and preliminary evidence against the concept of the “obesity paradox,” by demonstrating that patients with obesity may be more likely to have worse outcomes after recanalization therapy than patients without obesity [4, 22]. We verified our findings in additional sensitivity analyses using a dichotomized obesity classification (BMI ≥ 30 vs <30 kg/m²), which yielded results consistent with the three-group analysis.
There are several possible explanations for the worse outcomes observed in patients with obesity. Obesity is associated with a state of chronic low-grade systemic inflammation, characterized by elevated levels of pro-inflammatory adipokines such as interleukin-6 and tumor necrosis factor-alpha, which may exacerbate secondary brain injury after ischemic stroke. Furthermore, altered adipokine profiles, including reduced levels of adiponectin, may impair cerebrovascular function and neuroplasticity, potentially limiting recovery [23]. Although stroke severity as assessed by the baseline NIHSS was similar in all three groups, hemiparesis leading to a disabling stroke may have a disproportionately negative impact on functional outcome in patients with obesity due to reduced physical resilience and impaired mobility as reported by Sheffler et al. [24]. In line with this observation, Miwa et al. found an increased likelihood of severe disability (mRS 5–6) at hospital discharge in patients with obesity (BMI ≥ 30.0 kg/m²) with AIS due to large artery atherosclerosis (aOR 1.44; 95% CI 1.01–2.17) [25].
General obesity-related factors such as more frequent self-reported dyspnea and reduced mobility can impede recovery [26]. Although diabetes and hypertension, which can complicate rehabilitation and prognosis, are frequent in obesity, their prevalence did not differ between BMI groups with the exception of arterial hypertension, which was more frequent in the obesity group in the three-group analysis [27]. In our cohort, the rates of obesity-associated complications at one year, including deep vein thrombosis, pulmonary embolism, gastrointestinal bleeding, and recurrent stroke, did not differ between weight groups (Table 2), and successful reperfusion (eTICI 2b–3) was achieved at comparable rates across groups (Table 1). These findings suggest that excess weight itself, rather than comorbidities or differences in reperfusion therapies, may primarily contribute to the poorer functional outcomes observed in stroke patients with obesity.
Finally our study demonstrated no difference in the incidence of MACE between patients with and without obesity at 1 year, consistent with previous findings [7].
Even if preliminary, our findings highlight the importance of developing targeted rehabilitation strategies and better weight management for stroke patients, as obesity appears to be associated with impaired recovery.
Strengths and limitations
The main strength of our study was its prospective design with accurate measurement of weight and height, as well as the high completeness of data for key outcomes, including for the long-term follow-up.
However, there were several limitations. Firstly, we had a small sample size that fell short of the original target of 750 patients planned per protocol. This was because the study had to be terminated prematurely due to financial constraints and recruitment challenges. Post-hoc power analysis yielded 67% for the three weight groups analysis, which is below the conventional 80% threshold. Based on the observed effect size (24% versus 12% poor outcome at 3 months in the obesity versus normal-weight group), approximately 157 patients with obesity would have been required to reach 80% power at a two-sided α = 0.05. Our findings should therefore be considered exploratory and hypothesis-generating, and require confirmation in larger cohorts. However, despite this underpower, the findings for primary outcome remained statistically significant. Secondly, potential residual confounding from unmeasured factors, such as comorbidities that were not taken into account (e.g., cancer, chronic diseases) or variations in the post-stroke care provided, may have influenced recovery in ways not fully captured by our analyses. Information concerning the quality and duration of rehabilitation and the social status of patients has not been collected. This information could have influenced functional recovery and should be taken into account in future studies. Thirdly, the recommended rt-PA dose for IVT is capped at 90 mg regardless of body weight, which may reduce treatment efficacy in patients weighing more than 100 kg. A subgroup analysis restricted to patients weighing <100 kg was performed to address this potential source of bias; the association between obesity and poor functional outcome at 3 months remained significant in this subgroup (aOR 3.42; 95% CI 1.33–8.78), suggesting that the worse outcomes observed in patients with obesity are not solely explained by potentially insufficient rt-PA dosing in patients weighing ≥100 kg. Whether the current 90 mg cap on alteplase remains appropriate for patients with obesity warrants further investigation in dedicated dose-finding studies. Fourthly, twenty-seven patients (10%) were lost to follow-up between the 3-month and 1-year visits, which may have introduced attrition bias in the 1-year analyses.
Conclusion
In the ISOT Study, obesity in stroke patients treated with recanalization therapy was associated with worse functional outcomes at 3 months, with a persistent trend at 1 year, providing preliminary evidence against the ‘obesity paradox’. Overweight was not associated with poorer outcomes. Given the limited sample size and statistical power, these findings should be interpreted as exploratory, preliminary and hypothesis-generating. They highlight the need for confirmation in larger prospective cohorts, for further research to elucidate the mechanisms underlying the association between obesity and impaired recovery after AIS, and for the development of targeted rehabilitation strategies for stroke patients with obesity.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13. https://doi.org/10.1056/NEJMoa020245.
Abarca-Gómez L, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, Acosta-Cazares B, Acuin C, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390:2627–42. https://doi.org/10.1016/S0140-6736(17)32129-3.
Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33:673–89. https://doi.org/10.1007/s40273-014-0243-x.
Amundson DE, Djurkovic S, Matwiyoff GN. The obesity paradox. Crit Care Clin. 2010;26:583–96. https://doi.org/10.1016/j.ccc.2010.06.004.
Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156:13–22. https://doi.org/10.1016/j.ahj.2008.02.014.
Niedziela J, Hudzik B, Niedziela N, Gąsior M, Gierlotka M, Wasilewski J, et al. The obesity paradox in acute coronary syndrome: a meta-analysis. Eur J Epidemiol. 2014;29:801–12. https://doi.org/10.1007/s10654-014-9961-9.
Dehlendorff C, Andersen KK, Olsen TS. Body mass index and death by stroke. JAMA Neurol. 2014;71:978. https://doi.org/10.1001/jamaneurol.2014.1017.
Liu Z, Sanossian N, Starkman S, Avila-Rinek G, Eckstein M, Sharma LK, et al. Adiposity and outcome after ischemic stroke. Stroke. 2021;52:144–51. https://doi.org/10.1161/STROKEAHA.119.027900.
Hassan AE, Chaudhry SA, Jani V, Grigoryan M, Khan AA, Adil MM, et al. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke? J Stroke Cerebrovasc Dis. 2013;22:545–9. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.01.022.
Gensicke H, Wicht A, Bill O, Zini A, Costa P, Kägi G, et al. Impact of body mass index on outcome in stroke patients treated with intravenous thrombolysis. Eur J Neurol. 2016;23:1705–12. https://doi.org/10.1111/ene.13071.
Pirson FAV, Hinsenveld WH, Staals J, de Greef BTA, van Zwam WH, Dippel DWJ, et al. The effect of body mass index on outcome after endovascular treatment in acute ischemic stroke patients: a post hoc analysis of the MR CLEAN trial. Cerebrovasc Dis. 2019;48:200–6. https://doi.org/10.1159/000504744.
Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44:2064–89. https://doi.org/10.1161/STR.0b013e318296aeca.
Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation. 1996;94:1167–74. https://doi.org/10.1161/01.CIR.94.5.1167.
Turc G, Bhogal P, Fischer U, Khatri P, Lobotesis K, Mazighi M, et al. European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. J Neurointerv Surg. 2023;15:e8–e8. https://doi.org/10.1136/neurintsurg-2018-014569.
Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41. https://doi.org/10.1161/01.STR.24.1.35.
Doehner W, Schenkel J, Anker SD, Springer J, Audebert HJ. Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial. Eur Heart J. 2013;34:268–77. https://doi.org/10.1093/eurheartj/ehs340.
Kim Y, Kim CK, Jung S, Yoon BW, Lee SH. Obesity-stroke paradox and initial neurological severity. J Neurol Neurosurg Psychiatry. 2015;86:743–7. https://doi.org/10.1136/jnnp-2014-308664.
Li H, Khan S, Siddique R, Bai Q, Liu Y, Zhang R, et al. Obesity in acute ischaemic stroke patients treated with intravenous thrombolysis therapy. Neurol Res. 2023;45:796–803. https://doi.org/10.1080/01616412.2021.1939486.
Branscheidt M, Schneider J, Michel P, Eskioglou E, Kaegi G, Stark R, et al. No impact of body mass index on outcome in stroke patients treated with IV thrombolysis BMI and IV thrombolysis outcome. PLoS One. 2016;11:e0164413 https://doi.org/10.1371/journal.pone.0164413.
Bouslama M, Perez HJ, Barreira CM, Haussen DC, Grossberg JA, Belagaje SR, et al. Body mass index and clinical outcomes in large vessel occlusion acute ischemic stroke after endovascular therapy. Interv Neurol. 2019;8:144–51. https://doi.org/10.1159/000496703.
Seet RCS, Zhang Y, Wijdicks EFM, Rabinstein AA. Thrombolysis outcomes among obese and overweight stroke patients: an age- and national institutes of health stroke scale–matched comparison. J Stroke Cerebrovasc Dis. 2014;23:1–6. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.04.001.
Ovbiagele B, Bath PM, Cotton D, Vinisko R, Diener HC. Obesity and recurrent vascular risk after a recent ischemic stroke. Stroke. 2011;42:3397–402. https://doi.org/10.1161/STROKEAHA.111.624957.
Mihaela A, Cercel A, Doeppner TR, Hermann DM, Surugiu R, Pirscoveanu DF, et al. Review: Systemic inflammation after stroke. Therapy and perspective. GeroScience. 2026;48:2179–2200. https://doi.org/10.1007/s11357-025-02070-1.
Sheffler LR, Knutson JS, Gunzler D, Chae J. Relationship between body mass index and rehabilitation outcomes in chronic stroke. Am J Phys Med Rehabil. 2012;91:951–6. https://doi.org/10.1097/PHM.0b013e31826458c6.
Miwa K, Nakai M, Yoshimura S, Sasahara Y, Wada S, Koge J, et al. Clinical impact of body mass index on outcomes of ischemic and hemorrhagic strokes. Int J Stroke. 2024. https://doi.org/10.1177/17474930241249370.
Santos M, Kitzman DW, Matsushita K, Loehr L, Sueta CA, Shah AM. Prognostic importance of dyspnea for cardiovascular outcomes and mortality in persons without prevalent cardiopulmonary disease: the atherosclerosis risk in communities study. PLoS One. 2016;11:e0165111. https://doi.org/10.1371/journal.pone.0165111.
Bailey RR, Serra MC, McGrath RP. Obesity and diabetes are jointly associated with functional disability in stroke survivors. Disabil Health J. 2020;13:100914. https://doi.org/10.1016/j.dhjo.2020.100914.
Funding
This research was supported by grants from the Bangerter Foundation, the Hermann Klaus Foundation, and the Swiss Heart Foundation. Open access funding provided by University of Bern.
Author information
Author notes
These authors contributed equally: Morin Beyeler, Hakan Sarikaya.
Authors and Affiliations
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
Moritz C. Kielkopf, Martina Goeldlin, Adrian Scutelnic, Sebastian D. Kaufmann, Anna Boronylo, Thomas R. Meinel, David J. Seiffge, Philipp Bücke, Mirjam R. Heldner, Marcel Arnold, Urs Fischer, Simon Jung, Morin Beyeler & Hakan Sarikaya
Department of Neurology, , USZ, Zürich University Hospital and University of Zürich, Zürich, Switzerland
Corinne Inauen, Andreas Luft, Christoph Globas & Susanne Wegener
CTU Bern, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Mattia Branca
Institute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
Johannes Kaesmacher
Authors
- Moritz C. Kielkopf
- Corinne Inauen
- Mattia Branca
- Martina Goeldlin
- Adrian Scutelnic
- Sebastian D. Kaufmann
- Anna Boronylo
- Johannes Kaesmacher
- Thomas R. Meinel
- David J. Seiffge
- Philipp Bücke
- Mirjam R. Heldner
- Andreas Luft
- Christoph Globas
- Marcel Arnold
- Urs Fischer
- Simon Jung
- Susanne Wegener
- Morin Beyeler
- Hakan Sarikaya
Contributions
MK contributed to conception and design, interpretation of data and writing of the publication. CI, MG, and AB. TM contributed to data acquisition, interpretation of data and critical revision of the manuscript for important intellectual content. MB contributed to analysis and interpretation of data and critical revision of the manuscript for important intellectual content. SW contributed to conception and design, interpretation of the data and critical revision of the manuscript for important intellectual content. MBe contributed to conception and design, data acquisition, analysis and interpretation of data, writing of the publication and provided supervision. HS contributed to conception and design, interpretation of data, critical revision of the publication for important intellectual content and provided supervision. All other authors contributed to interpretation of data and critical revision of the manuscript for important intellectual content.
Corresponding author
Correspondence to Moritz C. Kielkopf.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The study protocol was approved by the Cantonal Ethics Committee Bern, Switzerland (Project ID PB_2016-01984) and conducted in accordance with the Declaration of Helsinki.
Consent to participate
Written informed consent to participate was obtained from all participants or, where necessary, from their legal representatives prior to enrolment.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kielkopf, M.C., Inauen, C., Branca, M. et al. Stroke outcomes in patients with obesity undergoing recanalization therapy. Int J Obes (2026). https://doi.org/10.1038/s41366-026-02253-6
Received: 11 September 2025
Revised: 01 September 2026
Accepted: 14 October 2026
Published: 12 November 2026
Version of record: 12 November 2026
DOI: https://doi.org/10.1038/s41366-026-02253-6
来源:Nature 健康护理主题 · nature.com